PHASE-II EVALUATION OF MITOXANTRONE PLUS CISPLATINUM IN PATIENTS WITH ADVANCED BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY

被引：5
|
作者：
ATIBA, JO
GREEN, SJ
HYNES, HE
OSBORNE, CK
MILLER, TP
DAVIDNER, M
机构：
[1] UNIV CALIF IRVINE,COLL MED,IRVINE,CA 92717
[2] SW ONCOL GRP,CTR STAT,SEATTLE,WA
[3] WICHITA CCOP,WICHITA,KS
[4] UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX
[5] UNIV ARIZONA,ARIZONA CANC CTR,TUCSON,AZ 85724
[6] KANSAS CITY CLIN ONCOL PROGRAM,KANSAS CITY,MO
来源：
INVESTIGATIONAL NEW DRUGS | 1994年 / 12卷 / 02期
关键词：
CISPLATINUM; MITOXANTRONE; BREAST CANCER; PHASE I-II TRIAL;
D O I：
10.1007/BF00874442
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m(2) to 12.0 mg/m(2)) and cis-platinum (100 mg/m(2)) in 30 patients with advanced breast cancer as second-line therapy. There were 2 partial responses in 29 eligible patients. Toxicity was considerable, with 27 patients having grade 3 or 4 toxicity. Grade 3-4 toxicity included vomiting, thrombocytopenia, granulocytopenia, leukopenia and anemia. The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer.
引用
收藏
页码：129 / 132
页数：4
相关论文
共 50 条
  • [1] PHASE-II EVALUATION OF HEXAMETHYLMELAMINE IN ADVANCED BREAST-CANCER - SOUTHWEST-ONCOLOGY-GROUP STUDY
    FABIAN, CJ
    RASMUSSEN, S
    STEPHENS, R
    HAUT, A
    SMITH, F
    BALCERZAK, S
    TRANUM, B
    CANCER TREATMENT REPORTS, 1979, 63 (08): : 1359 - 1361
  • [2] PHASE-II EVALUATION OF VP-16-213 IN PATIENTS WITH ADVANCED BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    VAUGHN, CB
    PANETTIERE, F
    THIGPEN, T
    BOTTOMLEY, R
    HOOGSTRATEN, B
    SAMAL, B
    CANCER TREATMENT REPORTS, 1981, 65 (5-6): : 443 - 445
  • [3] PHASE-II TRIAL OF MITOXANTRONE IN ADVANCED SARCOMAS - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    BULL, FE
    VONHOFF, DD
    BALCERZAK, SP
    STEPHENS, RL
    PANETTIERE, FJ
    CANCER TREATMENT REPORTS, 1985, 69 (02): : 231 - 233
  • [4] PHASE-II EVALUATION OF MITOXANTRONE IN ADVANCED PANCREATIC-CARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    TAYLOR, SA
    FLEMING, T
    VONHOFF, DD
    MCCRACKEN, JD
    BUKOWSKI, RM
    TALLEY, RW
    NATALE, RB
    GUY, JT
    SAMLOWSKI, WE
    COSTANZI, JH
    INVESTIGATIONAL NEW DRUGS, 1990, 8 (01) : 77 - 80
  • [5] PHASE-II TRIAL OF PIROXANTRONE IN METASTATIC BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    RAVDIN, PM
    GREEN, S
    DOROSHOW, JH
    MARTINO, S
    INVESTIGATIONAL NEW DRUGS, 1994, 12 (04) : 333 - 336
  • [6] PHASE-II EVALUATION OF AMONAFIDE IN ADVANCED SARCOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    BUYS, SS
    METCH, B
    BALCERZAK, SP
    NEEFE, JR
    STUCKEY, WJ
    CANCER INVESTIGATION, 1994, 12 (04) : 399 - 402
  • [7] RANDOMIZED TRIAL OF DOXORUBICIN, BISANTRENE, AND MITOXANTRONE IN ADVANCED BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    COWAN, JD
    NEIDHART, J
    MCCLURE, S
    COLTMAN, CA
    GUMBART, C
    MARTINO, S
    HUTCHINS, LF
    STEPHENS, RL
    VAUGHAN, CB
    OSBORNE, CK
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (15): : 1077 - 1084
  • [8] PHASE-II STUDY OF PLATINUM AND MITOXANTRONE IN METASTATIC PROSTATE-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    OSBORNE, CK
    BLUMENSTEIN, BA
    CRAWFORD, ED
    WEISS, GR
    BUKOWSKI, RM
    LARRIMER, NR
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) : 477 - 478
  • [9] PHASE-II TRIAL OF AMONAFIDE IN ADVANCED PANCREAS CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    LEICHMAN, CG
    TANGEN, C
    MACDONALD, JS
    LEIMERT, T
    FLEMING, TR
    INVESTIGATIONAL NEW DRUGS, 1993, 11 (2-3) : 219 - 221
  • [10] A PHASE-II STUDY OF MITOXANTRONE IN ADVANCED BREAST-CANCER
    THOMPSON, PI
    HARVEY, VJ
    MEDICAL AND PEDIATRIC ONCOLOGY, 1987, 15 (03): : 142 - 142
12345